Tag #Clinical Trial

Showing 1 to 12 of 54 results

dw.com

🌐 90% Global Worthiness

Sep 26, 01:14

Huntington's Disease Progression Slowed by 75% in Clinical Trial

British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.

Huntington's Disease Progression Slowed by 75% in Clinical Trial

British researchers announced a 75% reduction in Huntington's disease progression over 36 months in a clinical trial of 29 patients using a new gene therapy, AMT-130, developed with UniQure.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the next steps and potential long-term implications of this breakthrough?

UniQure plans to seek accelerated FDA approval in early 2026, followed by UK and European applications. Successful approval would represent a major advance in treating this currently incurable disease, potentially improving patients' quality of life significantly.

edition.cnn.com

🌐 90% Global Worthiness

Sep 25, 10:19

UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression

A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.

UniQure's Gene Therapy Shows Promise in Slowing Huntington's Disease Progression

A Phase 1/2 study by uniQure showed a 75% reduction in Huntington's disease progression in patients receiving a high dose of AMT-130 gene therapy after 36 months, marking a potential breakthrough in treating this currently incurable condition.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary impact of uniQure's Phase 1/2 study results on Huntington's disease treatment?

The study's findings demonstrate a 75% reduction in Huntington's disease progression in patients given a high dose of AMT-130, representing a significant step towards the first disease-modifying treatment. This could fundamentally change the treatment landscape, moving beyond symptom management to directly slowing disease progression.

bbc.com

🌐 95% Global Worthiness

Sep 24, 16:19

Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression

A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.

Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression

A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this gene therapy work, and what are its limitations?

The therapy uses a modified virus to deliver a DNA sequence into the brain, silencing the gene responsible for producing the toxic huntingtin protein. The 12-18 hour neurosurgery involved limits accessibility due to complexity and anticipated high cost; the therapy's efficacy was shown in 29 patients and not yet peer-reviewed.

es.euronews.com

🌐 85% Global Worthiness

Sep 3, 10:14

Beta-blockers Ineffective for Some Post-Heart Attack Patients: REBOOT Trial

A major international study, REBOOT, found that beta-blockers provide no clear benefit for patients with normal heart function after uncomplicated heart attacks, and even increased mortality risk in women.

Beta-blockers Ineffective for Some Post-Heart Attack Patients: REBOOT Trial

A major international study, REBOOT, found that beta-blockers provide no clear benefit for patients with normal heart function after uncomplicated heart attacks, and even increased mortality risk in women.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of the REBOOT trial regarding beta-blocker efficacy after a heart attack?

The REBOOT trial, involving over 8,500 patients, found no significant difference in death, recurrent heart attack, or hospitalization rates between patients continuing or discontinuing beta-blockers after an uncomplicated heart attack. However, a notable increased risk of death and hospitalization was observed in women taking beta-blockers.

news.sky.com

🌐 85% Global Worthiness

Aug 11, 19:19

Pancreatic Cancer Vaccine Shows Promise in Early Trials

A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...

Pancreatic Cancer Vaccine Shows Promise in Early Trials

A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the new pancreatic cancer vaccine's success in early trials?

A new pancreatic cancer vaccine, ELI-002 2P, has shown promise in a phase 1 trial by slowing disease progression and increasing survival rates. In a study of 25 patients (20 with pancreatic cancer, 5 with bowel cancer), 68% developed a strong immune response after 20 months. Pancreatic cancer patients receiving the vaccine survived an average of 2 years and 5 months, significantly longer than the current average of one year.

foxnews.com

🌐 85% Global Worthiness

Aug 7, 07:19

New Glioblastoma Therapy Shows Promise in Clinical Trial

A New Jersey woman, Pamela Goldberger, 65, diagnosed with glioblastoma in 2023, is alive and healthy 2.5 years later after participating in a clinical trial for a new individualized dendritic cell therapy (DOC1021), showing promising results for this aggressive cancer.

New Glioblastoma Therapy Shows Promise in Clinical Trial

A New Jersey woman, Pamela Goldberger, 65, diagnosed with glioblastoma in 2023, is alive and healthy 2.5 years later after participating in a clinical trial for a new individualized dendritic cell therapy (DOC1021), showing promising results for this aggressive cancer.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the DOC1021 therapy work, and what were the key findings of the phase 1 clinical trial?

The clinical trial, led by Dr. Joseph Georges, involved 16 patients with newly diagnosed glioblastoma. The treatment, DOC1021, primes the immune system to target the tumor cells, showing positive immune responses and improved survival with minimal side effects. This is a significant development, as glioblastoma survival rates haven't improved in 20 years.

liberation.fr

🌐 90% Global Worthiness

Sep 25, 22:16

Huntington's Disease Treatment Shows Significant Progress

British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.

Huntington's Disease Treatment Shows Significant Progress

British researchers announced a new gene therapy that slowed Huntington's disease progression by 75% in a clinical trial of 29 patients over 36 months, offering a potential breakthrough for the 6,000 individuals in France affected by this neurodegenerative disorder.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the future implications and limitations of this gene therapy?

While promising, further testing is needed to evaluate long-term effects, potential side effects, and overall efficacy. The success in this trial suggests a potential paradigm shift in Huntington's disease treatment, offering hope for improved quality of life for patients, but larger-scale trials and extended follow-up are crucial before widespread application.

cnnespanol.cnn.com

🌐 90% Global Worthiness

Sep 25, 07:18

Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression

A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.

Experimental Gene Therapy Shows Significant Slowdown in Huntington's Disease Progression

A Phase 1/2 study by uniQure showed that a high dose of their gene therapy, AMT-130, slowed Huntington's disease progression by 75% in patients after 36 months, marking a potential breakthrough for the currently incurable disease.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the next steps and potential future implications of this research?

uniQure plans to submit data to the FDA in Q1 2026, with potential market launch by the end of 2027 if approved. While further research is necessary, this success could accelerate the development of similar one-time, precision gene therapies for other neurological diseases. The reduction in neurofilament light protein levels further supports the positive effects of this treatment.

theguardian.com

🌐 85% Global Worthiness

Sep 10, 04:18

£100 Blood Test for Alzheimer's in UK Clinical Trial

A UK clinical trial is testing a £100 blood test for Alzheimer's disease on 1,100 patients to assess its impact on diagnosis speed and treatment decisions, aiming to improve care for the over 500,000 UK residents with the condition.

£100 Blood Test for Alzheimer's in UK Clinical Trial

A UK clinical trial is testing a £100 blood test for Alzheimer's disease on 1,100 patients to assess its impact on diagnosis speed and treatment decisions, aiming to improve care for the over 500,000 UK residents with the condition.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary goal of this clinical trial, and what are its potential immediate impacts?

The trial aims to determine if a new £100 blood test speeds up Alzheimer's diagnosis and improves patient care. Positive results could lead to faster diagnosis and treatment for the over 500,000 UK Alzheimer's patients, potentially improving their quality of life.

elpais.com

🌐 85% Global Worthiness

Aug 30, 13:17

Millions Unnecessarily Take Beta-Blockers After Heart Attack: Study

A clinical trial involving 8,500 patients in Spain and Italy revealed that beta-blockers provide no benefit for most heart attack survivors and may be harmful to women, prompting calls to reconsider their widespread use.

Millions Unnecessarily Take Beta-Blockers After Heart Attack: Study

A clinical trial involving 8,500 patients in Spain and Italy revealed that beta-blockers provide no benefit for most heart attack survivors and may be harmful to women, prompting calls to reconsider their widespread use.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the broader implications of this research and its potential effects on healthcare systems and patient care?

This research suggests millions worldwide are unnecessarily taking beta-blockers, incurring potential side effects and healthcare costs. Revised guidelines and more selective prescribing could lead to significant cost savings and improved patient outcomes by reducing unnecessary medication and potential adverse effects, especially among women.

elpais.com

🌐 85% Global Worthiness

Aug 11, 22:16

Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations

An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.

Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations

An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the promising results from the ELI-002 vaccine trial for pancreatic cancer patients?

In Spain, cancer survival rates have doubled in the last four decades, reaching 55% for men and 62% for women five years post-diagnosis. A new experimental cancer vaccine, ELI-002, shows promising results in a small trial, extending the time before cancer recurrence in patients with pancreatic cancer who had undergone surgery and chemotherapy.

es.euronews.com

🌐 75% Global Worthiness

Aug 2, 10:14

French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment

A French clinical trial is testing photobiostimulation to treat Parkinson's disease by targeting mitochondria in deep brain neurons; early results show symptom improvement in three of seven patients with continuous stimulation.

French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment

A French clinical trial is testing photobiostimulation to treat Parkinson's disease by targeting mitochondria in deep brain neurons; early results show symptom improvement in three of seven patients with continuous stimulation.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of this research for Parkinson's treatment if the ongoing trial shows sustained positive results?

If successful, this photobiostimulation approach could significantly impact Parkinson's treatment, potentially slowing disease progression for a larger patient population than current medication or electrode stimulation. Further trials are planned to determine the long-term effectiveness and widespread applicability of this technology.

Showing 1 to 12 of 54 results